As policymakers and industry leaders prepare to gather at Interclean 2026, new insights highlight the significant economic and societal contribution of Europe’s tissue sector – an often overlooked but essential pillar of daily life, hygiene, and public health.

According to ETS’ latest socioeconomic impact analysis, the tissue industry:

• Supports over 421,000 jobs across Europe, with employment extending far beyond manufacturing into retail, logistics, and services
• Generates €19.7 billion in annual revenue, highlighting the sector’s role in Europe’s industrial and economic ecosystem
• Delivers 8.2 million tonnes of essential tissue products each year, supporting hygiene in homes, healthcare, and public spaces
• Plays a critical role in hygiene standards, particularly in healthcare settings, public facilities, and high-traffic environments

At a time when Europe is navigating complex discussions around sustainability, public health, and industrial policy, these findings underscore the importance of a balanced, evidence-based approach to hygiene solutions.

“Tissue products are a cornerstone of modern hygiene systems,” said Carlos Reinoso, Director General of the European Tissue Symposium (ETS). As policymakers consider future regulations, it is essential to recognise both the economic contribution of our sector and the critical role tissue plays in protecting public health. Decisions must be grounded in science, lifecycle thinking, and real-world usage.”

The findings contribute to the broader sustainability debate by highlighting the importance of lifecycle thinking, hygiene performance, and practical implementation.

Meet ETS at Interclean 2026

ETS will be present at Interclean 2026, engaging with policymakers, industry stakeholders, and media to discuss the implications of the study for Europe’s regulatory and sustainability landscape.

Journalists and attendees are invited to connect with ETS on-site to explore:

• The full socioeconomic impact of the tissue industry
• The role of tissue in maintaining hygiene and public health
• The importance of evidence-based policymaking in sustainability discussions

Media Opportunities

• On-site meetings with ETS representatives
• Access to key data and insights from the socioeconomic impact study
• Expert commentary on hygiene, sustainability, and regulatory developments

To arrange a meeting or interview, please contact:
Nadia Del Rio | press@europeantissue.com

The foundation of this personalized approach is the human genome. Since the completion of the Human Genome Project, the cost of sequencing an individual’s DNA has plummeted, making it increasingly accessible as a standard diagnostic tool. When clinicians utilize personalized medicine advancing targeted treatment, they are not just looking at a patient’s external symptoms but are instead reading the very blueprint of their biological existence. This genomic data allows for the identification of specific genetic mutations or variations that may predispose an individual to certain cancers, cardiovascular diseases, or rare genetic disorders. By understanding these vulnerabilities before they manifest as full-blown clinical conditions, the medical community can implement preventive strategies that were previously impossible, effectively stopping the disease in its tracks or managing it far more effectively from its earliest stages.

The Role of Biomarker Research in Precision Treatment

A critical component of personalized medicine advancing targeted treatment is the identification and validation of biomarkers. Biomarkers are biological indicators ranging from specific proteins in the blood to patterns of gene expression in a tumor that provide a snapshot of a patient’s health or their likely response to a particular therapy. In the field of oncology, biomarker research has been particularly transformative. Instead of treating all lung or breast cancers with the same broad-spectrum chemotherapy, doctors can now test for specific markers like EGFR or HER2. This information is the essence of personalized medicine advancing targeted treatment, as it allows for the selection of a drug that specifically targets the molecular driver of that individual’s cancer, while sparing healthy cells from the toxic side effects of traditional treatments. This targeted approach not only increases the efficacy of the treatment but also preserves the patient’s quality of life during a very difficult period.

Moreover, biomarker research is expanding into other areas of medicine, such as psychiatry and immunology. For example, identifying specific inflammatory markers can help rheumatologists determine which biologic therapy will be most effective for a patient with rheumatoid arthritis. In mental health, researchers are looking for genetic markers that can predict how a patient will metabolize antidepressants, reducing the trial-and-error phase that often plagues psychiatric care. This precision treatment model ensures that the patient receives the right dose of the right medicine at the right time. By integrating these biological insights, personalized medicine advancing targeted treatment is reducing the burden of adverse drug reactions, which are currently a leading cause of hospitalizations and mortality worldwide.

Genomic Medicine and Data-Driven Insights

The true power of personalized medicine advancing targeted treatment is realized when vast amounts of genomic and clinical data are integrated through advanced computational analysis. The field of pharmacogenomics, which studies how genes affect a person’s response to drugs, is a prime example of this synergy. By analyzing large datasets, researchers can identify subtle genetic variations that influence drug metabolism, allowing for the development of companion diagnostics that are used alongside a medication to ensure its safe and effective use. This level of personalized medicine advancing targeted treatment is becoming the standard for many new drug approvals, as regulatory bodies like the FDA and EMA recognize that the average patient is a statistical myth that can lead to suboptimal care and unnecessary risk.

However, the transition to genomic medicine requires a sophisticated digital infrastructure. Data must be stored securely, analyzed accurately, and presented to the clinician in a way that is actionable at the point of care. This is where artificial intelligence and machine learning are playing an increasingly vital role. These technologies can sift through millions of data points to find patterns that the human eye might miss, such as a rare combination of genetic variants that increases the risk of a specific type of heart failure. By providing these insights to the physician, personalized medicine advancing targeted treatment empowers the human expert to make more informed decisions, blending clinical experience with the most advanced biological data available. The result is a more robust, evidence-based approach to patient care that honors the unique complexity of human biology.

Targeted Therapy Development and the Future of Care

The pharmaceutical industry is also being reshaped by the principles of personalized medicine advancing targeted treatment. The development of new therapies is increasingly focused on orphan diseases and specific molecular subtypes of common conditions. This shift is driven by the realization that a drug that works exceptionally well in a small, genetically defined group is more valuable than a drug that works moderately well for everyone. This targeted therapy development is leading to breakthroughs in fields like gene therapy and mRNA technology, where the treatment is essentially a customized piece of biological code designed to correct a specific genetic defect. This is the ultimate expression of personalized medicine advancing targeted treatment a therapy that is not just for the patient but is a part of the patient.

As we look toward the future, the integration of real-world evidence from wearable devices and electronic health records will further refine the personalized medicine advancing targeted treatment model. Imagine a system where your genomic profile is combined with real-time data on your sleep, diet, and stress levels to provide personalized health recommendations. This holistic view of the individual will allow for a truly precision lifestyle, where the focus is on maintaining health rather than just treating disease. The ethical and privacy considerations of such a system are significant, but the potential to extend human life and reduce the global burden of chronic illness is unparalleled. By continuing to invest in personalized medicine advancing targeted treatment, we are paving the way for a more equitable and effective healthcare system where every individual is seen, understood, and treated as the unique biological entity they are.

Ethical and Practical Considerations in Precision Medicine

The transition to personalized medicine advancing targeted treatment is not without its challenges. One of the primary concerns is ensuring equitable access to these advanced technologies. Currently, genomic sequencing and targeted therapies can be expensive, potentially creating a divide between those who can afford precision care and those who cannot. To fully realize the promise of personalized medicine advancing targeted treatment, the healthcare industry must work together to lower costs and integrate these tools into standard clinical practice. This includes updating insurance reimbursement models to recognize the long-term value of preventive genomic screening and targeted interventions, which can prevent much more costly hospitalizations and chronic complications later in life.

Additionally, the management of genetic data poses significant privacy risks. Patients must be confident that their genomic information will be protected and used only for their benefit. Clear ethical guidelines and robust cybersecurity measures are essential components of the personalized medicine advancing targeted treatment ecosystem. As we navigate these complexities, the focus must remain on the patient. The goal is to create a healthcare system that is not only technologically advanced but also deeply human and compassionate. By leveraging the power of personalized medicine advancing targeted treatment, we are moving closer to a future where precision is synonymous with care, and where the uniqueness of the individual is the very center of the medical journey.

However, a recent expansion from LinusBio is aiming to close that gap. The company announced that its biomarker-based test, ClearStrand™ASD, is now available for children up to age 10, moving well beyond its previous cutoff of 48 months. This shift comes at a critical time, as the CDC now estimates that 1 in 31 children in the U.S. are identified with autism spectrum disorder.

A “Biological Diary” in a Strand of Hair

The most striking thing about the test is the sample it requires: a single strand of hair. While traditional blood or urine tests only show a “snapshot” of a child’s health at one specific moment, hair acts as a longitudinal record.

LinusBio uses a combination of robotics and laser-based analysis to “read” the elemental data deposited in the hair over time. This allows them to reconstruct a timeline of how a child’s biology has interacted with their environment, an approach they call “exposomic sequencing”. Remarkably, just one centimeter of hair can yield data equivalent to roughly 1,000 sequential blood measurements.

Streamlining the System

ClearStrand™ASD is designed as a “rule-out” test. With a 95% negative predictive value, it gives clinicians a high level of confidence to exclude autism as a diagnosis. In practice, this means families can be redirected toward the right care pathways immediately—such as speech therapy or sensory support—rather than waiting years for an evaluation they might not actually need.

The Scientist Behind the Breakthrough: Dr. Manish Arora

While his titles are impressive, he is the Edith J. Baerwald Professor and Vice Chairman at the Icahn School of Medicine at Mount Sinai, Dr. Manish Arora’s work is driven by a simple goal: providing families with clarity.

An environmental epidemiologist by trade, Dr. Arora pioneered the use of tooth and hair samples to look back in time at environmental exposures, even reaching back to the prenatal period. His career has been dedicated to moving away from purely behavioral assessments, which can be influenced by cultural context or access to care, and toward objective biological data.

Despite his international recognition as a researcher, Dr. Arora often notes that his roles as a husband and father are just as central to his work as his time in the lab. It’s this perspective that fuels his commitment to early detection, offering families the “transformative” power of timely intervention.

The Historical Context and Technological Leap Forward

To truly appreciate the current state of clinical diagnostics, one must first look back at the origins of radiology. For over a century, the field was defined by the transition from static, two-dimensional shadows to the sophisticated, multi-layered digital environments we see today. The journey from the first rudimentary X-ray to the high-field MRI units of the present day is a testament to human ingenuity. However, the most significant leap has not just been in the hardware itself, but in the software that interprets the massive amounts of data these machines generate. This is where medical imaging innovation improving diagnostic accuracy truly begins to take shape, transforming raw data into actionable clinical insights that save lives daily.

In the early days of medical imaging, the primary challenge was simply getting a clear enough picture to see an abnormality. Radiologists spent years training their eyes to catch the slightest variation in pixel density on a physical film. Today, the challenge has shifted from a lack of data to an overwhelming abundance of it. Modern diagnostic imaging systems produce thousands of slices per scan, creating a volumetric representation of the human body that is so detailed it requires computational assistance to navigate. This shift from physical film to digital volumetric data has laid the groundwork for a more collaborative and precise diagnostic environment, where experts from around the world can view and analyze the same high-fidelity images in real-time.

The Role of Artificial Intelligence in Modern Radiology

Artificial intelligence is no longer a futuristic concept in the world of medicine it is a current reality that is fundamentally altering the workflow of every modern imaging department. AI imaging software serves as a sophisticated filter, identifying patterns that are too subtle for the human eye to consistently detect. These algorithms are trained on datasets containing millions of confirmed clinical cases, allowing them to provide a level of statistical certainty that was previously unattainable. When medical imaging innovation improving diagnostic accuracy is supported by these intelligent systems, the rate of false negatives in critical areas like oncology and cardiology drops significantly, ensuring that patients receive the interventions they need at the earliest possible stage.

The integration of machine learning into radiology innovation goes beyond simple detection. It involves the quantification of disease markers that were previously subjective. For instance, instead of a radiologist estimating the size of a nodule, the software can provide a precise measurement down to the sub-millimeter level, along with an analysis of its density and shape. This level of granularity is essential for tracking the progression of a disease over time. By providing a baseline of objective data, AI imaging software allows clinicians to make more informed decisions about whether a treatment is working or if a change in strategy is required. This synergy between human expertise and machine precision is the hallmark of the modern diagnostic era.

Optimizing the Diagnostic Workflow for Clinical Excellence

Efficiency in the radiology department is not just about speed it is about ensuring that the most critical cases are identified and reviewed with the highest priority. Precision diagnostic workflows leverage automation to triage scans as they are completed. If a system detects a potential intracranial hemorrhage or a pulmonary embolism, it can instantly move that scan to the top of the worklist and alert the on-call specialist. This immediate triaging is a direct result of medical imaging innovation improving diagnostic accuracy, as it reduces the “wait time” for high-stakes diagnoses where every second counts. By optimizing how data flows through the hospital, these systems save lives before a doctor even enters the room.

Furthermore, the reduction of diagnostic fatigue is a significant benefit of these automated systems. Radiologists often review hundreds of scans in a single shift, a task that is mentally and visually taxing. Automation handles the repetitive aspects of the job such as segmenting organs or identifying historical comparisons allowing the specialist to focus their cognitive energy on the complex interpretive work that requires a human touch. This balanced approach not only improves the accuracy of each individual reading but also promotes the long-term well-being of the healthcare workforce. When technology handles the heavy lifting of data processing, the human clinician is empowered to be a more effective healer.

The Personalization of Healthcare Imaging Solutions

Every patient is unique, and the modern approach to diagnostics recognizes that a one-size-fits-all strategy is no longer sufficient. Healthcare imaging solutions are increasingly being tailored to the specific genetic and physiological profile of the individual. For example, in pediatric radiology, the focus is on minimizing radiation exposure while maintaining high diagnostic quality. Advanced reconstruction algorithms can now produce high-resolution images from low-dose scans, protecting the long-term health of young patients. This commitment to “as low as reasonably achievable” (ALARA) principles is a core component of medical imaging innovation improving diagnostic accuracy, as it ensures that the diagnostic process itself does no harm.

In the realm of personalized oncology, imaging is being combined with genomic data to create a comprehensive view of a patient’s health. This field, known as radiomics, extracts thousands of features from medical images that are invisible to the naked eye. These features can predict how a specific tumor will respond to chemotherapy or immunotherapy, allowing doctors to select the most effective treatment from the outset. This move away from trial-and-error medicine toward a more predictive and precise model is perhaps the most exciting frontier of medical imaging technology. It represents a future where the image is not just a snapshot of the present, but a roadmap for the patient’s recovery.

Advancements in Volumetric and Molecular Imaging

The transition from two-dimensional slices to three-dimensional volumetric imaging has revolutionized surgical planning and patient education. Surgeons can now “fly through” a patient’s anatomy using virtual reality tools before they ever step into the operating room. They can identify the exact location of blood vessels, nerves, and tumors, allowing for a more minimally invasive and precise procedure. This level of preparation is a direct outcome of medical imaging innovation improving diagnostic accuracy, as it bridges the gap between the diagnostic suite and the surgical theater. When a surgeon knows exactly what they will encounter, the risk of intraoperative complications is significantly reduced.

Molecular imaging represents the next great hurdle in our understanding of disease. Unlike traditional imaging, which looks at the structure of organs, molecular imaging looks at their function. By using specialized tracers, clinicians can see the metabolic activity of cells in real-time. This is particularly useful for identifying the early stages of neurodegenerative diseases like Alzheimer’s or Parkinson’s, often years before structural changes are visible on a standard scan. The ability to see the “hidden” signals of disease at a molecular level is a testament to the power of radiology innovation. It provides a level of foresight that was previously the stuff of science fiction, allowing for interventions that can slow or even halt the progression of debilitating conditions.

Bridging the Gap: Tele-Radiology and Global Connectivity

The benefits of advanced imaging should not be limited by geography. One of the most significant impacts of modern diagnostic imaging systems is the ability to share data across the globe instantaneously. Tele-radiology platforms allow specialists in metropolitan centers to provide expert interpretations for patients in rural or underserved areas. This democratization of expertise ensures that a patient in a remote village has access to the same high-level diagnostic certainty as a patient in a world-class teaching hospital. This global connectivity is a vital part of medical imaging innovation improving diagnostic accuracy, as it ensures that the best minds in medicine are available whenever and wherever they are needed.

Furthermore, these cloud-based platforms facilitate collaborative research on a scale never before possible. Researchers can pool anonymized imaging data from thousands of institutions to identify new trends and develop more effective diagnostic criteria. This collective intelligence accelerates the pace of innovation, leading to new software tools and hardware improvements that benefit the entire medical community. The synergy between local care and global research creates a feedback loop of continuous improvement, where every scan contributes to a deeper understanding of human health. As we continue to build these digital bridges, the future of radiology looks more connected and more precise than ever before.

Conclusion: The Ethical Imperative of Precision Diagnostics

As we look toward the future, the ongoing medical imaging innovation improving diagnostic accuracy is more than just a technological trend it is an ethical imperative. We have a responsibility to provide patients with the most accurate information possible about their health. Every advancement in software, every improvement in hardware, and every refinement in workflow is a step toward a more just and effective healthcare system. By reducing the margin of error and increasing the speed of diagnosis, we are not just improving metrics we are preserving the human stories that these images represent.

The journey of innovation is never truly complete. There will always be new diseases to understand, new technologies to master, and new ways to improve the patient experience. However, the foundation has been laid. With the integration of AI, the rise of molecular imaging, and the commitment to personalized care, the field of radiology is better equipped than ever to meet the challenges of the 21st century. The ultimate goal remains clear: a world where no diagnosis is missed, every treatment is targeted, and every patient can look forward to a healthy future with confidence. This is the promise of medical imaging technology, and it is a promise we are fulfilling one image at a time.

The Impact of Evolving Global Regulations on MedTech

The shift from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) in the European Union has set a new global benchmark for safety and performance. This transition has significantly increased the requirements for clinical evidence and post-market surveillance, forcing many manufacturers to re-evaluate their entire product portfolios. A successful medical device innovation and regulatory strategy must now account for these more stringent requirements, ensuring that every claim made about a device’s performance is backed by rigorous, peer-reviewed clinical data. This regulatory shift is not confined to Europe; other major markets, including the United States and China, are also tightening their oversight, making a unified global strategy essential for any company looking to compete on the world stage.

Clinical Validation as a Strategic Pillar

In the modern regulatory environment, clinical validation has moved from being a final hurdle to a continuous process. Manufacturers are increasingly using real-world evidence (RWE) to supplement traditional clinical trials, providing a more comprehensive view of how a device performs in diverse patient populations. By integrating RWE into their medical device innovation and regulatory strategy, companies can identify potential safety issues much earlier and gather the data necessary to support expanded indications for use. This data-driven approach not only satisfies regulatory requirements but also provides healthcare providers and payers with the evidence they need to justify the adoption of new technologies.

Quality Assurance and the Importance of ISO 13485

At the heart of any successful device manufacturing operation is a robust quality management system (QMS). The ISO 13485 standard remains the international gold standard for medical device quality assurance, providing a framework that ensures consistent design, development, and production processes. However, as devices become more complex, the scope of the QMS must also expand. A forward-looking medical device innovation and regulatory strategy integrates quality assurance into every stage of the lifecycle, from initial concept to end-of-life disposal. This “quality by design” philosophy ensures that potential failure modes are identified and mitigated during the development phase, rather than being discovered after the product has reached the market.

Risk Management in the Era of Connected Devices

The rise of the Internet of Medical Things (IoMT) has introduced a new set of risks that must be addressed within the regulatory framework. Cybersecurity is no longer an optional consideration but a core component of medical device compliance. A comprehensive medical device innovation and regulatory strategy must include a detailed plan for managing software vulnerabilities and ensuring data privacy across the entire ecosystem. This involves not only securing the device itself but also the networks and cloud platforms it interacts with. Regulators now expect manufacturers to provide detailed documentation of their cybersecurity measures, as well as a plan for ongoing monitoring and patching of software throughout the device’s lifecycle.

Navigating the Path to Global Market Access

Gaining regulatory approval is only the first step; achieving sustainable market access requires a deep understanding of the reimbursement landscape and the needs of healthcare providers. A well-crafted medical device innovation and regulatory strategy bridges the gap between clinical success and commercial viability. This involves engaging with health technology assessment (HTA) bodies early in the development process to understand what evidence they require to demonstrate value. In many cases, this may mean collecting data on long-term patient outcomes or economic impacts, which goes beyond the safety and performance data required for initial regulatory approval.

Accelerated Pathways and Regulatory Harmonization

To encourage the development of life-saving technologies, many regulators have introduced accelerated approval pathways, such as the FDA’s Breakthrough Devices Program. Leveraging these programs is a key component of an effective medical device innovation and regulatory strategy, as it provides manufacturers with more frequent interactions with the agency and a prioritized review process. Furthermore, the industry is moving toward greater regulatory harmonization through initiatives like the Medical Device Single Audit Program (MDSAP). By participating in these programs, manufacturers can streamline the audit process and gain access to multiple global markets more efficiently, reducing the administrative burden and speeding up the delivery of innovation to patients.

The Role of Software as a Medical Device (SaMD)

As digital health continues to evolve, the definition of a medical device is expanding to include standalone software. Software as a Medical Device (SaMD) presents unique regulatory challenges, as software can be updated much more frequently than hardware. A modern medical device innovation and regulatory strategy must therefore include a robust plan for managing software changes and ensuring that updates do not compromise the safety or performance of the application. This often involves the use of “pre-certification” models, where the regulator focuses on the culture of quality and organizational excellence of the developer, rather than reviewing every individual code change.

Artificial Intelligence and Machine Learning in Diagnostics

The integration of AI and machine learning into medical devices is perhaps the most transformative trend in the industry today. These technologies have the potential to revolutionize diagnostics, providing clinicians with unprecedented insights and improving patient outcomes. However, the “black box” nature of some AI algorithms poses significant regulatory hurdles. An effective medical device innovation and regulatory strategy for AI-driven technologies must focus on transparency, explainability, and the continuous monitoring of the algorithm’s performance in a real-world setting. Regulators are increasingly looking for “algorithmic change protocols” that define how an AI model will be retrained and validated as it encounters new data.

Sustainable Device Manufacturing and Circular Economy

In addition to technological and regulatory challenges, the medical device industry is facing increasing pressure to address its environmental impact. Sustainable device manufacturing is becoming a key differentiator for companies looking to align with the values of healthcare systems and patients. A comprehensive medical device innovation and regulatory strategy now includes considerations for the entire product lifecycle, from the selection of recyclable materials to the implementation of “take-back” programs for used devices. By adopting circular economy principles, manufacturers can reduce waste, lower their carbon footprint, and often find new efficiencies in their supply chains.

Future-Proofing through Regulatory Intelligence

The only constant in the MedTech industry is change. To remain competitive, companies must invest in regulatory intelligence the ongoing process of monitoring and analyzing the evolving regulatory landscape. By integrating this intelligence into their medical device innovation and regulatory strategy, manufacturers can anticipate future requirements and adjust their development plans accordingly. This proactive approach minimizes the risk of regulatory surprises and ensures that the company remains at the forefront of innovation while maintaining the highest standards of safety and compliance.

The convergence of clinical excellence, technological innovation, and regulatory foresight is the defining characteristic of the modern medical device landscape. While the challenges are significant, the opportunities to improve patient care through advanced diagnostics, personalized treatments, and connected care are greater than ever before. By developing and executing a holistic medical device innovation and regulatory strategy, manufacturers can navigate the complexities of global market access, ensure long-term compliance, and ultimately deliver life-changing technologies to the people who need them most.

This surge in innovation is not occurring in a vacuum. It is the result of decades of foundational research in genomics and proteomics, coupled with a more collaborative approach to translational research. The clinical pipeline of the modern era is no longer a linear path but a dynamic ecosystem where data from the clinic informs the lab, and breakthroughs in the lab are rapidly accelerated toward patient trials. This synergy is ensuring that the global medical community is prepared to address the most pressing health challenges of our time, from rare genetic disorders to the complexities of aging.

Advanced Biologics and the Precision Medicine Revolution

At the forefront of biotech innovation strengthening clinical pipelines is the development of advanced biologics. Unlike traditional drugs, which are chemically synthesized, biologics are complex molecules derived from living organisms. This allow them to interact with the body with a level of specificity that was previously impossible. Monoclonal antibodies, for example, can be designed to seek out and attach to specific proteins on the surface of cancer cells, flagging them for destruction by the immune system while leaving healthy cells untouched.

The clinical pipeline development for these therapies is increasingly focused on “precision therapies” that are tailored to the specific molecular profile of a disease. In oncology, this means moving away from a “one-size-fits-all” chemotherapy toward treatments that are selected based on the genetic mutations of the patient’s tumor. This targeted approach significantly improves the efficacy of the treatment while drastically reducing the side effects, leading to a much higher quality of life for the patient. As our ability to engineer these complex molecules grows, the range of conditions that can be addressed by biologics will only continue to expand.

Regenerative Medicine: Healing from Within

Perhaps the most ambitious frontier of biotech innovation strengthening clinical pipelines is regenerative medicine. This field seeks to replace or “reboot” damaged tissues and organs through the use of stem cell therapies, tissue engineering, and gene therapy. We are moving toward a future where a failing heart or a damaged spinal cord could potentially be repaired using the patient’s own biological material.

Gene therapy, in particular, is proving to be a game-changer for rare, inherited disorders. By delivering a functional copy of a gene directly into a patient’s cells, clinicians can address the root cause of a disease rather than just managing its symptoms. Several such therapies are already in clinical trials for conditions like hemophilia and muscular dystrophy, showing promise for what could essentially be a one-time cure. This shift from chronic management to curative intervention is a fundamental change in the medical philosophy, made possible by the relentless pace of biotech innovation.

Translational Research: Bridging the Bench and the Bedside

The journey from a laboratory discovery to a bedside treatment is notoriously long and expensive. However, biotech innovation strengthening clinical pipelines is being accelerated by new models of translational research. This approach prioritizes the “real-world” applicability of research from the very beginning, ensuring that scientific discoveries are developed with the clinical end-goal in mind.

Modern translational research utilizes “in silico” modeling using powerful computers to simulate how a drug will interact with the human body before it ever enters a clinical trial. This allows researchers to identify potential safety issues or efficacy problems early in the process, saving years of time and millions of dollars. Furthermore, the rise of adaptive clinical trial designs allows for the modification of a trial in real-time based on the incoming data, ensuring that the most promising therapies are moved forward as quickly as possible. This agility is essential for maintaining a healthy and productive clinical pipeline in a rapidly changing medical landscape.

Strategic Collaboration and the Global Biotech Ecosystem

Innovation in biotech is increasingly a team sport. Small, agile biotech startups are often the source of the most radical new ideas, while large pharmaceutical companies provide the resources and expertise necessary to navigate the complex regulatory and manufacturing challenges. This collaborative ecosystem is vital for biotech innovation strengthening clinical pipelines, as it allows for the efficient sharing of risk and reward.

We are also seeing an increase in public-private partnerships, where academic institutions, government agencies, and private industry work together to address unmet medical needs. This is particularly important for the development of “orphan drugs” for rare diseases that might not be commercially viable for a single company to pursue alone. By pooling resources and expertise, these global networks are ensuring that the most innovative therapies are not left on the lab bench due to a lack of funding or infrastructure.

The Role of Digital Health in Clinical Development

The digitization of healthcare is also playing a significant role in clinical pipeline development. Real-world evidence (RWE) data collected from electronic health records, insurance claims, and even wearable devices is increasingly being used to supplement traditional clinical trial data. This provide researchers with a clearer understanding of how a therapy performs in a diverse, real-world population, beyond the controlled environment of a trial.

AI is also being used to identify new drug targets by analyzing vast datasets of genetic and clinical information. By identifying hidden correlations between specific biological markers and disease outcomes, AI can point researchers toward new avenues for therapy that they might never have considered. This data-driven approach to discovery is significantly shortening the “discovery-to-pipeline” phase, ensuring a constant stream of new candidates for clinical testing.

Ethical Considerations and the Future of Biotech

As we push the boundaries of what is biologically possible, we must also grapple with the ethical implications. Technologies like CRISPR-based gene editing offer immense promise but also raise significant questions about the long-term impacts on the human genome and the potential for misuse. Biotech innovation strengthening clinical pipelines must be guided by a robust ethical framework and transparent regulatory oversight to ensure that the benefits are realized safely and equitably.

Access to these cutting-edge therapies is another critical issue. Many of the most innovative biologics and gene therapies are incredibly expensive to produce, leading to concerns about who will be able to afford them. The industry must work with healthcare systems and policymakers to develop new pricing and reimbursement models that balance the need for innovation with the need for broad patient access. The ultimate goal of biotech is to improve human health, and that goal is only fully realized when these breakthroughs reach everyone who needs them.

A Vision for a Curative Future

The future of biotech is one of boundless potential. We are entering an era where we no longer just treat disease, but we edit it, reprogram it, and regenerate the damage it leaves behind. Through the continued strength of the clinical pipeline, we are building a toolkit of precision therapies that will transform the human experience of illness.

Biotech innovation is more than just a business; it is a profound expression of our collective ingenuity and our commitment to relieving human suffering. As we continue to unlock the secrets of life at the molecular level, we are not just strengthening a pipeline; we are strengthening our hope for a healthier and more resilient future for all. The vanguard of therapy is here, and it is leading us toward a new horizon of healing.

The MiniMed Go Smart MDI system is designed for people with insulin-requiring type 1 and type 2 diabetes aged seven years and older, as well as children aged two to six under adult supervision. Medtronic said compatibility with its Simplera™ sensor is still under FDA review.

MiniMed Go provides real-time glucose insights, missed dose alerts, insulin dose calculations, and action-based guidance when doses are missed or miscalculated. The system also integrates with Medtronic’s CareLink™ software, allowing clinicians to review data and collaborate more easily with patients.

Medtronic said the system addresses a large unmet need among people managing diabetes with multiple daily injections, a group that represents more than 15 million individuals globally. Managing injections requires frequent carbohydrate estimation and dose calculation, a daily process that can lead to fatigue, stress, and missed doses over time.

Clinical and real-world data from Medtronic’s earlier Smart MDI systems show that timely responses to alerts can significantly improve glucose control. According to the company, Time in Range increased from 55.7% to 67.2% when users responded to more than 75% of missed dose alerts within one hour. Time in Range reached 71.5% when users corrected high glucose alerts with a bolus dose within an hour.

“For too long, people using injections have carried the weight of diabetes management without access to the algorithms that make automated insulin delivery systems so powerful,” said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. “MiniMed Go™ is designed to change that — bringing the smarts of an AID system to individuals who prefer an insulin pen. The system helps take the guesswork out of MDI therapy, delivering simplicity and confidence in every dose.”

Medtronic said it plans to begin the commercial rollout of MiniMed Go in the U.S. this spring.

Traditional randomized controlled trials, while scientifically rigorous, often investigate medications under carefully controlled conditions involving selected patient populations that may not represent actual clinical practice. Trial protocols specify restrictive inclusion/exclusion criteria, closely monitor participants, and follow standardized protocols that differ substantially from typical clinical settings. While this controlled approach provides scientifically robust efficacy data, it generates limited information regarding how treatments actually perform across diverse patient populations under real-world conditions. Real-world evidence addresses this limitation by documenting treatment performance in everyday clinical practice, revealing treatment effectiveness, safety patterns, and optimal patient populations in authentic healthcare environments. By leveraging real-world evidence to inform trial design and execution, organizations generate research findings more directly applicable to clinical decision-making and patient populations researchers aim to serve.

Real-world evidence represents an increasingly essential component of modern pharmaceutical development, complementing rather than replacing traditional trial evidence. Regulatory agencies recognize real-world evidence’s value for understanding treatment performance in diverse populations and identifying patient subgroups most likely to benefit from specific interventions. Organizations embracing real-world evidence integration will establish competitive advantages through better-informed trial designs, more relevant research evidence, and more efficient drug development. As healthcare systems continue prioritizing cost-effectiveness and treatment optimization, real-world evidence becomes increasingly critical for demonstrating value and appropriateness of therapeutic interventions across diverse patient populations.

Bridging the Gap Between Trial Results and Clinical Practice

Clinical trials conducted under controlled research conditions provide scientifically robust efficacy data but often involve patient populations and treatment settings differing substantially from actual clinical practice. Trial protocols typically exclude patients with significant comorbidities, advanced age, or complex medication regimens—populations representing substantial proportions of real-world patients receiving medications in routine clinical care. Furthermore, intensive monitoring, strict adherence requirements, and standardized protocols in trial settings differ markedly from typical clinical environments where patients receive less frequent monitoring and flexibility regarding treatment modification. Real-world evidence addresses this fundamental disconnect by documenting medication performance under authentic clinical conditions, revealing how treatments actually perform across diverse patient populations receiving care in varied healthcare settings.

Real-world evidence represents clinical data collected outside traditional trial environments, derived from established electronic health records systems, insurance claims databases, disease registries, and direct patient data collection through wearable devices. This pragmatic data captures genuine treatment effectiveness, safety patterns, medication adherence challenges, and disease progression trajectories under conditions closely approximating actual clinical practice. By leveraging real-world evidence throughout clinical development, organizations bridge the “evidence-to-practice gap” that frequently results in trial findings poorly predicting actual clinical outcomes. The transformation from research-generated efficacy data to clinically applicable effectiveness evidence represents a fundamental shift in how pharmaceutical organizations approach evidence generation and regulatory strategies.

Electronic Health Records and Comprehensive Patient Databases

Electronic health records represent one of the richest sources of real-world evidence, containing comprehensive clinical documentation, laboratory results, treatment histories, diagnostic codes, and clinical outcomes spanning patient populations across diverse healthcare systems. Machine learning algorithms mine these vast databases to identify patient cohorts matching specific clinical characteristics, extract treatment information regarding medication dosages and durations, and link treatment exposure to subsequent health outcomes. This systematic analysis of EHR data reveals natural experiment results—spontaneously occurring situations where similar patients receive different medications, enabling comparison of real-world treatment outcomes.

Real-world evidence derived from EHR analysis provides substantial advantages over trial-based evidence in several important respects. First, the patient populations represented in EHR databases reflect actual clinical practice—including elderly individuals, patients with significant comorbidities, and populations systematically excluded from traditional trials. Second, the diversity of healthcare settings represented provides insight into how treatments perform across hospitals, specialty clinics, primary care practices, and rural facilities. Third, the longitudinal nature of EHR data captures long-term treatment outcomes extending years beyond typical trial duration. Machine learning algorithms extract actionable insights from these comprehensive datasets, identifying which patient populations derive greatest benefit from specific medications and which patient subgroups experience unacceptable adverse effect burden.

Insurance Claims Data and Treatment Pattern Analysis

Insurance claims databases provide detailed information regarding medication utilization patterns, treatment discontinuation rates, and economic outcomes across large patient populations. By analyzing claims data, researchers identify which medications patients continue long-term and which medications patients discontinue shortly after initiation—information suggesting perceived efficacy and tolerability in real-world settings. Treatment persistence analysis derived from claims data often diverges from trial results, revealing that medications showing impressive efficacy in trials may suffer from poor long-term adherence due to side effects, inconvenience, or lack of perceived benefit in actual practice.

Machine learning algorithms analyzing claims data can identify treatment patterns predicting long-term medication discontinuation, suggesting that while trials demonstrated efficacy, practical tolerability or delivery factors limit real-world success. This insight enables trial designers to prioritize endpoints capturing factors important for real-world medication persistence—potentially identifying more relevant endpoints than traditional efficacy measures. Furthermore, claims data analysis reveals economic outcomes including healthcare utilization, hospitalizations, and treatment costs associated with specific medications under real-world conditions. This economic real-world evidence increasingly influences payer decisions regarding medication coverage and reimbursement, making real-world evidence essential for demonstrating value in today’s cost-conscious healthcare environment.

Patient Registries and Longitudinal Outcome Documentation

Disease registries capture longitudinal clinical data from patients with specific conditions, documenting disease progression, treatment approaches, and clinical outcomes over extended follow-up periods. Registry data represents real-world evidence combining spontaneously collected clinical information with standardized data collection protocols ensuring adequate data quality and comparability across participants. Patients with specific conditions including rare diseases, cancer, diabetes, and cardiovascular disease contribute to registries documenting their disease trajectory and treatment outcomes.

Machine learning algorithms applied to registry data can identify patient subgroups with superior or inferior treatment responses, predict disease progression patterns, and recommend personalized treatment approaches based on comparable patients’ experiences. By analyzing registry data, researchers identify which patients derived greatest benefit from specific medications—information invaluable for targeting trials toward responsive populations. Furthermore, registries often capture outcomes directly relevant to patients including functional status, quality of life, and disease impact—metrics often underrepresented in traditional trials emphasizing laboratory measures and clinician-assessed endpoints. Registry-derived real-world evidence regarding patient-centered outcomes increasingly influences regulatory decisions and healthcare provider treatment recommendations.

Wearable Devices and Continuous Health Monitoring Data

Wearable biosensors including smartwatches, fitness trackers, and specialized medical devices generate continuous real-world health data capturing daily living conditions and authentic treatment response patterns. Rather than relying on infrequent clinic-based measurements, wearables collect continuous information regarding activity levels, sleep patterns, heart rate variability, temperature, and other physiological parameters. This longitudinal data stream provides substantially richer information regarding treatment effect and disease progression compared to episodic measurements from traditional clinical encounters.

Real-world evidence from wearable devices reveals treatment effectiveness across diverse daily situations and reveals individual variation in treatment response that population-averaged trial results obscure. Analysis of wearable data can identify treatment effects appearing modest in population-averaged analyses but substantially improving functional capacity for specific patient subgroups. Machine learning algorithms analyzing wearable data from large populations can identify early warning signals predictive of treatment failure or emerging adverse effects, enabling early clinical intervention before serious complications develop. The continuous nature of wearable data transforms real-world evidence generation, providing disease and treatment outcome information with unprecedented granularity and temporal resolution.

Trial Design Optimization Through Real-World Insights

Organizations strategically leveraging real-world evidence can substantially improve clinical trial design and execution. Analysis of real-world treatment patterns guides inclusion/exclusion criteria development—rather than purely theoretical reasoning, trial designers can base criteria on evidence regarding which patient populations derive greatest real-world benefit. Real-world evidence analysis reveals patient subgroups with superior treatment responses, enabling trials to enrich for responsive populations and achieve higher efficacy signals compared to trials enrolling unselected patient samples.

Real-world evidence further informs endpoint selection by identifying which clinical outcomes matter most to actual patients and predict long-term treatment persistence. Trial designers discovering that certain outcomes predict real-world medication adherence better than other measures can prioritize these endpoints for trial evaluation. If real-world evidence demonstrates that patients discontinue medications despite trial-demonstrated efficacy due to side effects, trial designers prioritize side effect reduction rather than further efficacy optimization. This evidence-informed endpoint selection ensures trials investigate outcomes most relevant to clinical decision-making and patient populations actually using medications in practice.

Regulatory Strategy and Post-Marketing Surveillance

Regulatory agencies increasingly accept real-world evidence as complement to traditional trial data, particularly for demonstrating real-world safety, identifying new therapeutic indications, and supporting approval of treatments for additional patient populations. FDA issued guidance establishing frameworks for evaluating real-world evidence, enabling sponsors to submit RWE supporting regulatory submissions. Organizations strategically collecting high-quality real-world evidence can leverage this data to support regulatory applications more efficiently and convincingly than relying exclusively on expensive clinical trials.

Post-marketing surveillance using real-world evidence enables detection of safety issues and rare adverse effects that trials cannot feasibly identify before product launch. Real-world evidence from millions of patients using medications in diverse settings reveals side effects potentially affecting small patient subgroups in ways that trials involving thousands of participants cannot detect. Machine learning algorithms monitoring real-world evidence streams can identify emerging safety signals requiring clinical action, enabling faster regulatory response to serious adverse effects. By proactively monitoring real-world evidence post-marketing, organizations fulfill regulatory obligations regarding medication safety while generating valuable data informing clinical use guidelines and patient populations most likely to benefit.

Population Health and Treatment Optimization

Real-world evidence enables population health approaches where healthcare systems analyze their own patient populations’ treatment patterns and outcomes to optimize clinical practices. By understanding how their specific patient populations respond to medications and identifying patient characteristics predicting treatment success, healthcare organizations can develop population-specific treatment guidelines optimizing outcomes. Machine learning algorithms trained on organization-specific real-world evidence can recommend treatments most likely to succeed for particular patient subgroups within their population.

This population-specific approach to real-world evidence utilization enables dramatic improvements in treatment outcomes and healthcare efficiency. Rather than applying generic clinical guidelines developed from trial populations potentially differing from local populations, organizations can tailor recommendations to their specific patient characteristics and epidemiology. Patients derive benefit through more targeted treatments optimized for their specific clinical context. Healthcare organizations achieve superior outcomes and cost efficiency through elimination of ineffective treatment trials and faster achievement of therapeutic response. The future of healthcare increasingly involves this evidence-based, population-specific optimization of clinical practices informed by real-world evidence.

Data Quality and Machine Learning Validation

Effective real-world evidence utilization requires careful attention to data quality, completeness, and appropriate application of machine learning algorithms. Real-world datasets frequently contain missing data, coding errors, and incomplete information compared to carefully collected trial data. Machine learning algorithms must be validated to ensure conclusions regarding real-world evidence reflect genuine patterns rather than data artifacts or algorithmic errors. Organizations utilizing real-world evidence must invest in data quality assurance, algorithm validation, and appropriate statistical controls ensuring scientific rigor.

Furthermore, machine learning algorithms trained on real-world evidence may demonstrate bias reflecting underlying healthcare disparities or inappropriate clinical practices documented in source data. Algorithms trained on data reflecting racial disparities in clinical decision-making might perpetuate these disparities if deployed without careful bias detection and correction. Organizations utilizing real-world evidence must actively evaluate algorithmic performance across diverse patient populations, identify potential biases, and implement corrections ensuring fairness and appropriateness across all populations. By addressing these methodological challenges, organizations can leverage real-world evidence’ substantial power while maintaining scientific rigor and equity.

Strategic Integration Across Development Continuum

Leading pharmaceutical organizations are increasingly integrating real-world evidence systematically throughout drug development—from early-stage research hypothesis generation through post-marketing surveillance. Rather than viewing real-world evidence and clinical trials as competing approaches, forward-thinking organizations recognize that optimal evidence generation leverages both approaches strategically. Real-world evidence informs trial design, identifies relevant patient populations, and suggests meaningful endpoints. Clinical trials provide rigorous efficacy evidence under controlled conditions. Combined, these approaches generate evidence substantially more applicable to clinical decision-making than either approach independently.

Strategic real-world evidence integration enables organizations to generate compelling evidence demonstrating clinical value more efficiently than organizations relying exclusively on traditional trial approaches. By demonstrating that medications improve outcomes in real-world settings for diverse patient populations, organizations can achieve regulatory approval, payer coverage, and clinical adoption more readily than organizations producing only idealized trial data. As healthcare increasingly demands evidence of real-world effectiveness and appropriate patient population targeting, organizations excelling at real-world evidence generation will establish substantial competitive advantages.

Future Evolution and Precision Medicine Integration

Real-world evidence will increasingly integrate with precision medicine approaches, enabling highly tailored treatment recommendations based on individual patient characteristics and comparable patients’ experiences. Machine learning models trained on diverse real-world populations can make personalized predictions regarding individual treatment response, optimizing medication selection and dosage for each specific patient. As genomic data, wearable monitoring, and electronic health records integrate comprehensively, real-world evidence becomes increasingly granular and personalized.

The trajectory of real-world evidence demonstrates profound potential for transforming pharmaceutical development from population-averaged approaches toward precision, population-specific, and ultimately individualized treatment optimization. Healthcare organizations mastering real-world evidence utilization will establish themselves as leaders in evidence-based medicine, delivering superior outcomes through evidence-informed clinical decisions optimized for their specific patient populations. As patients increasingly expect treatment recommendations based on current evidence reflecting people similar to themselves, the importance of real-world evidence will only increase. The future of medicine clearly involves strategic integration of real-world evidence informing clinical decision-making at every level—individual patient care, organizational protocol development, regulatory decision-making, and healthcare policy development.

“These updated results align with previous findings and further demonstrate that CCH is both effective and well tolerated in men with Peyronie’s disease and ventral curvature,” said Peter Bajic, MD, Associate Professor of Urology and Director of Men’s Health at Cleveland Clinic’s Glickman Urological Institute and presenting author of the presentation. “This consistency is encouraging for both clinicians and patients seeking nonsurgical treatment options.”

The Endo-sponsored presentation is below:

• Collagenase Clostridium Histolyticum (CCH) for Ventral Curvature (VC) of the Penis Due to Peyronie’s Disease (PD): Updated Results From a Noninterventional, Retrospective, Multicenter Study
• Authors: Matthew J. Ziegelmann, MD; Billy H. Cordon, MD; Majdee M. Islam, MD; Alexander J. Tatem, MD; Richard C. Bennett, MD; Faysal A. Yafi, MD, FRCSC; Petar Bajic, MD; Nelson E. Bennett, Jr., MD; Helen L. Bernie, DO, MPH; Marcelo Mass-Lindenbaum, MD; Muhammed A. M. Hammad, MBBCh, MS; Kristen Gumpf, PA-C; James Tursi, MD; David Hurley, MD; Jeffrey Andrews, MS; Tina Rezakhani, PharmD, MBA; Marian Ayad, PharmD, BCPS; Mohit Khera, MD, MBA, MPH; Bruce R. Kava, MD; Jesse N. Mills, MD

About the Study

This Phase 4 multicenter, noninterventional, retrospective study evaluated the effectiveness and safety of CCH in adult men with PD and ventral curvature (VC). Researchers reviewed medical charts of patients aged 18 and older diagnosed with VC and a palpable plaque, treated with CCH between 2014 and each site’s study start date.

The primary endpoint was percent change in penile VC, while secondary endpoints included mean degree change in penile VC and the proportion of patients achieving at least 30% improvement in penile VC from baseline to last visit.

No serious or severe treatment-related adverse events were reported, and there were no cases of urethral involvement or injury.

These updated findings reinforce that CCH is effective and well tolerated in men with PD and VC, supporting its continued use as a nonsurgical treatment option for this population.

About Peyronie’s Disease

Peyronie’s disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2 but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.3

XIAFLEX® INDICATION

XIAFLEX® is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

IMPORTANT SAFETY INFORMATION

Do not receive XIAFLEX if:

• the Peyronie’s plaque to be treated involves the “tube” that your urine passes through (urethra).
• you are allergic to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.

XIAFLEX can cause serious side effects, including:

1.  Penile fracture (corporal rupture) or other serious injury to the penis. Receiving an injection of XIAFLEX may cause damage to the tubes in your penis called the corpora. After treatment with XIAFLEX, one of these tubes may break during an erection. This is called a corporal rupture or penile fracture. This could require surgery to fix the damaged area. Damage to your penis might not get better after a corporal rupture.

• After treatment with XIAFLEX, blood vessels in your penis may also break, causing blood to collect under the skin (hematoma). This could require a procedure to drain the blood from under the skin. If a hematoma appears, skin and soft tissue necrosis (death of skin cells) may develop in that area, which could require surgery.

Symptoms of corporal rupture or other serious injury to your penis may include:

• a popping sound or sensation in an erect penis
• sudden loss of the ability to maintain an erection
• pain in your penis
• purple bruising and swelling of your penis
• difficulty urinating or blood in the urine

Call your healthcare provider right away if you have any of the symptoms of corporal rupture or serious injury to the penis listed above.

Do not have sex or any other sexual activity between the first and second injections of a treatment cycle.

Do not have sex or have any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with XIAFLEX and after any pain and swelling has gone away.

XIAFLEX for the treatment of Peyronie’s disease is only available through a restricted program called the XIAFLEX Risk Evaluation and Mitigation Strategy (REMS) Program.

2. Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX, because it contains foreign proteins.

Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:

• hives
• swollen face
• breathing trouble
• chest pain
• low blood pressure
• dizziness or fainting

3. Back pain reactions. After receiving an injection of XIAFLEX for Peyronie’s disease, you may suddenly feel back pain, including severe lower back pain moving to your legs, feet, chest and arms. The back pain may also include spasms and make it hard to walk. These symptoms usually go away in 15 minutes or less, but may last longer.

Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.

4. Fainting. Fainting (passing out) or near fainting can happen in men who receive XIAFLEX, especially if they have severe penile pain.

If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away.

Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.

What should I avoid while receiving XIAFLEX?

Avoid situations that may cause you to strain your stomach (abdominal) muscles, such as straining during bowel movements.

Do not use a vacuum erection device during your treatment with XIAFLEX.

XIAFLEX can cause serious side effects, including increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.

The most common side effects with XIAFLEX for the treatment of Peyronie’s disease include:

• a small collection of blood under the skin at the injection site (hematoma)
• swelling at the injection site or along your penis
• pain or tenderness at the injection site, along your penis and above your penis
• penis bruising
• itching of your penis or scrotum (genitals)
• painful erection
• erection problems (erectile dysfunction)
• changes in the color of the skin of your penis
• blisters at the injection site
• pain with sex
• a lump at the injection site (nodule)

Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

WHAT IS XIAFLEX?

XIAFLEX is a prescription medicine used to treat adult men with Peyronie’s disease who have a “plaque” that can be felt and a curve in their penis greater than 30 degrees when treatment is started.

It is not known if XIAFLEX is safe and effective in children under the age of 18.